China, Finland To Set Up Pharmaceutical Industry Fund
This article was originally published in PharmAsia News
Finland and China investors will jointly set up a €30 million industry fund that exclusively invests in early-stage development of China's biopharmaceutical projects and supports their internationalization. Finnish Industry Investment Ltd., part of Finland's Ministry of Trade and Industry, will assume most of the country's €15 million investment with private capital making up the rest. Three Chinese private investors are in discussions and the Finns hope to secure government interest as well. The fund is also part of Finland's biotech health project that seeks collaboration with China's universities in R&D and offers services for Chinese products entering Europe. However, analysts point out that no proper exit strategy is in place, which could deter investors' participation. (Click here for more - Chinese Language)
You may also be interested in...
Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.
Nomolotus discontinued social media claims that its herbal supplement supports users’ immune systems during the COVID-19 pandemic and customers reviews referencing the virus after the National Advertising Division questioned the statements as misleading.
A PwC analysis finds biopharma aggregate deal value declined 87% during the first half compared to the second half of 2018; deal volume dropped 17%. The pandemic was a cause, but not the only factor.